<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Health Qual Life Outcomes</journal-id><journal-id journal-id-type="iso-abbrev">Health Qual Life Outcomes</journal-id><journal-title-group><journal-title>Health and Quality of Life Outcomes</journal-title></journal-title-group><issn pub-type="epub">1477-7525</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27016084</article-id><article-id pub-id-type="pmc">4807577</article-id><article-id pub-id-type="publisher-id">449</article-id><article-id pub-id-type="doi">10.1186/s12955-016-0449-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0583-0882</contrib-id><name><surname>Smyth</surname><given-names>Emily Nash</given-names></name><address><email>nash_smyth_emily@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Wei</given-names></name><address><email>shen@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Bowman</surname><given-names>Lee</given-names></name><address><email>bowman_lee_lb@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Peterson</surname><given-names>Patrick</given-names></name><address><email>peterson_patrick@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>John</surname><given-names>William</given-names></name><address><email>john_william_j@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Melemed</surname><given-names>Allen</given-names></name><address><email>melemed_allen@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Liepa</surname><given-names>Astra M.</given-names></name><address><email>liepa_astra_m@lilly.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>25</day><month>3</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>14</volume><elocation-id>52</elocation-id><history><date date-type="received"><day>2</day><month>7</month><year>2015</year></date><date date-type="accepted"><day>9</day><month>3</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Smyth et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Patient-reported outcomes have been associated with survival in numerous studies across cancer types, including breast cancer. However, the Brief Pain Inventory-Short Form (BPI-SF) and the Rotterdam Symptom Checklist (RSCL) have rarely been investigated in this regard in breast cancer.</p></sec><sec><title>Methods</title><p>Here we describe a post hoc analysis of the prognostic effect of baseline scores of these instruments on survival in a phase III trial of patients with advanced breast cancer who received gemcitabine plus paclitaxel or paclitaxel alone after anthracycline-based adjuvant or neoadjuvant therapy. The variables for this analysis were baseline BPI-SF &#x0201c;worst pain&#x0201d; and BPI-SF &#x0201c;pain interference&#x0201d; scores, and four RSCL subscales (each transformed to 0&#x02013;100). Univariate and multivariate Cox models were used, the latter in the presence of 11 demographic/clinical variables. Kaplan-Meier curves and log-rank tests were used to compare survival for patients by BPI-SF or RSCL scores.</p></sec><sec><title>Results</title><p>Of 529 randomized patients, 286 provided BPI-SF data and 336 provided RSCL data at baseline. Univariate analyses identified BPI-SF worst pain and pain interference (both hazard ratios [HR], 1.07 for a 1-point increase; both <italic>p</italic>&#x02009;&#x02264;&#x02009;0.0061) and three of four RSCL subscales [activity level, physical distress, and health-related quality of life (HRQOL) (HR, 0.86&#x02013;0.91 for 10-point increase all <italic>p</italic>&#x02009;&#x02264;&#x02009;0.0104)], to have significant prognostic effect for survival. BPI-SF worst pain (<italic>p</italic>&#x02009;=&#x02009;0.0342) and RSCL activity level (<italic>p</italic>&#x02009;=&#x02009;0.0004) were prognostic in the multivariate analysis. Median survival for patients categorized by BPI-SF worst pain score was 23.8 (<italic>n</italic>&#x02009;=&#x02009;91), 17.9 (<italic>n</italic>&#x02009;=&#x02009;94) and 14.6 (<italic>n</italic>&#x02009;=&#x02009;94) months for scores 0, 1&#x02013;4, and 5&#x02013;10, respectively (log-rank <italic>p</italic>&#x02009;=&#x02009;0.0065). Median survival was 23.8 and 14.6&#x000a0;months for patients (<italic>n</italic>&#x02009;=&#x02009;330) with above- and below-median RSCL activity level scores respectively (log-rank <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001).</p></sec><sec><title>Conclusion</title><p>Pretreatment BPI-SF worst pain and RSCL activity scores provide distinct prognostic information for survival in patients receiving paclitaxel or gemcitabine plus paclitaxel for advanced breast cancer even after controlling for multiple demographic and clinical factors.</p></sec><sec><title>Trial registration</title><p>Clinicaltrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT00006459">NCT00006459</ext-link>.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cancer pain</kwd><kwd>Quality of life</kwd><kwd>Breast cancer</kwd><kwd>Prognostic factors</kwd><kwd>Treatment outcomes</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/http://dx.doi.org/10.13039/100004312</institution-id><institution>Eli Lilly and Company (US)</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Breast cancer is the most common malignancy worldwide and the largest cause of cancer-related death in women [<xref ref-type="bibr" rid="CR1">1</xref>]. With advancements across screening and treatment modalities over the past 3 decades, evidence from institutional databases and clinical trials [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] suggests that patients with metastatic breast cancer (MBC) are surviving longer than the median of 18&#x02013;24 months that has been traditionally reported [<xref ref-type="bibr" rid="CR4">4</xref>]. However, it unfortunately still remains an incurable disease in nearly all instances, and the goal of treatment is to palliate or prevent symptoms, delay disease progression, and prolong survival [<xref ref-type="bibr" rid="CR4">4</xref>]. Patients living with advanced disease can experience diminished health-related quality of life (HRQOL) due to cancer- and treatment-related symptoms, such as pain, fatigue, cognitive dysfunction, sleep disturbances, arm morbidity, neuropathy, and menopausal symptoms [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Self- report from cancer patients provides a unique perspective that addresses aspects of wellbeing, feelings, and functioning, which may not be otherwise captured with standard clinical assessments [<xref ref-type="bibr" rid="CR7">7</xref>]. Patients who have reported worsening of symptoms and HRQOL have also experienced deterioration in their clinical condition [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Research has shown that HRQOL-related information can serve as a useful adjunct to conventional clinical assessments for oncology patients by improving patient-clinician communication and, in particular, helping clinicians understand patient challenges from a psychosocial perspective [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Understanding all of these factors is increasingly important in oncology in order to optimize the care of patients [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>Patient-reported outcome data obtained from validated instrumentation have demonstrated consistency and reliability in association with clinical outcomes for cancer and non-cancer conditions [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Given the increasing potential for such data to be clinically informative [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>], patient-reported outcomes and symptoms have emerged as important measures of cancer treatment in clinical trials. Stratifying patients in clinical trials by baseline HRQOL can result in more homogeneous treatment groups and allow for better understanding of study results [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Patient-reported outcomes, assessed via a variety of different instruments, have shown independent prognostic value for survival in post hoc analyses of clinical trials [<xref ref-type="bibr" rid="CR26">26</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>] and in observational studies of MBC patients undergoing cancer treatment [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The prognostic value of HRQOL and associated domains has also been demonstrated in an exploratory fashion across other solid-tumor-specific studies, [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>] as well as in systematic reviews and meta-analyses [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. A recent analysis of 7417 patients examined the relative value of different HRQOL domains for multiple cancer types using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30). Results demonstrated that HRQOL parameters of greatest prognostic value differed by cancer type, and the effect size of each parameter varied according to tumor site. For breast cancer as well as other cancer types, at least one domain provided additional prognostic information to that obtained from clinical and sociodemographic variables [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>The current report is an exploratory, post hoc analysis of clinical and HRQOL outcomes from a phase III trial comparing gemcitabine plus paclitaxel with paclitaxel alone in patients with advanced breast cancer. As previously reported [<xref ref-type="bibr" rid="CR40">40</xref>], patients receiving doublet therapy experienced significantly improved survival versus paclitaxel alone and were also more likely to have improved HRQOL over time as measured by the Brief Pain Inventory-Short Form (BPI-SF) and Rotterdam Symptom Checklist (RSCL). Here we evaluate the prognostic effect of BPI-SF and RSCL baseline scores on survival. The BPI-SF is used extensively in clinical practice [<xref ref-type="bibr" rid="CR41">41</xref>] and it has been used across many studies in breast cancer to assess pain. To our knowledge, however, this is the first exploratory report evaluating the prognostic significance of baseline pain and the relationship to survival utilizing this instrument. Other studies in advanced breast cancer to date have utilized the RSCL [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>] although none have reported the prognostic significance of baseline scores. The current analysis therefore adds to the body of research by evaluating the prognostic effect of baseline scores for pain and other HRQOL domains on survival in advanced breast cancer utilizing the BPI-SF and the RSCL.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><sec id="Sec3"><title>Study design</title><p>This was a post hoc analysis of a phase III, multinational, clinical trial evaluating paclitaxel with and without gemcitabine in women with advanced breast cancer who relapsed after adjuvant or neoadjuvant therapy with an anthracycline, or non-anthracycline if there was a contraindication (Clinicaltrials.gov identifier NCT00006459). As reported by Albain et al. [<xref ref-type="bibr" rid="CR40">40</xref>], eligible patients were to have had Karnofsky Performance Status (KPS)&#x02009;&#x02265;&#x02009;70, adequate bone marrow reserve, liver and renal function, normal calcium levels, and an estimated life expectancy of &#x02265;12&#x000a0;weeks at baseline. Prior systemic treatment for metastatic disease was not allowed. Patients were randomly allocated to paclitaxel, with or without concurrent gemcitabine, and treatment cycles continued until disease progression, unacceptable toxicity, or patient withdrawal. There were 529 randomized patients from 19 countries. The primary endpoint was overall survival, which was defined as the time from randomization to death from any cause, and surviving patients were censored at the last visit date. Patients completed the BPI-SF and the RSCL within 1 week prior to randomization and at the end of each treatment cycle. Both the questionnaires were completed by patients for whom validated translations were available. The RSCL was included in this study to better understand the impact of treatment on patient&#x02019;s symptoms and the influence of symptoms on physical and psychological function. The BPI-SF was included to allow a more focused evaluation of pain, which is not specifically evaluated by the RSCL. Efficacy, safety, and patient-reported outcomes results have been previously reported [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR45">45</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. The study was conducted according to Declaration of Helsinki and good clinical practice guidelines, and was approved by each participating center&#x02019;s ethics review board. All patients signed informed consent forms that described the clinical and HRQOL components of the study.</p></sec><sec id="Sec4"><title>Patient-reported outcome instrumentation</title><p>The BPI-SF is a valid and reliable instrument [<xref ref-type="bibr" rid="CR41">41</xref>], originally developed to assess chronic pain and its impact on HRQOL [<xref ref-type="bibr" rid="CR47">47</xref>]. This instrument is widely used in clinical practice settings and research to measure the impact of cancer pain [<xref ref-type="bibr" rid="CR41">41</xref>]. Patients rate their pain and its effects as experienced in the preceding 24&#x000a0;hours. The BPI-SF measures pain intensity (worst, least, average, current), pain relief, and interference of pain (on 7 HRQOL dimensions of general activity, mood, walking, normal work, relations with others, sleep, and enjoyment of life). Scores for the worst pain item as well as pain interference were used in this analysis. Worst pain scores range from 0 (no pain) to 10 (worst pain). Pain interference scores range from 0 (no interference) to 10 (complete interference) and were calculated as the mean of the seven pain interference items.</p><p>The RSCL is a validated instrument for measuring HRQOL and symptoms in cancer patients [<xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. The instrument assesses symptoms and effects of symptoms on anxiety, depression, functional status, and quality of life during the week prior to completing the questionnaire. It has been used previously by patients with advanced breast cancer [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR50">50</xref>], as well as in numerous other cancer trials [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR55">55</xref>]. Patients answer items for different symptoms via a Likert scale (not at all, a little, quite a bit, very much) comprising four dimensions: physical distress (23 items), psychological distress (7 items), activity level (8 items), and a single item to measure overall HRQOL. For the purposes of this study, the RSCL subscales were each transformed to 0&#x02013;100, with 100 as the best score.</p></sec><sec id="Sec5"><title>Statistical analyses</title><p>The present post hoc analysis utilized patient-reported outcome scores measured at baseline only. All patients with a baseline BPI-SF or RSCL assessment were included, and data from the two study treatment arms were combined for all analyses.</p><p>The associations between baseline measures of clinician-assessed KPS and patient-assessed BPI-SF and RSCL subscale scores were analyzed using one-way analyses of variance (ANOVA). Univariate Cox proportional hazards models were used to determine the prognostic effect of each variable on survival. Multivariate Cox proportional hazard models were used to determine the prognostic effect of each RSCL and BPI-SF score in the presence of 11 baseline demographic and clinical prognostic factors that had been used in the clinical study for randomization stratification or preplanned subgroup analyses. In general, a finding of an effect in a univariate analysis is sufficient to show that the subscale provides prognostic information for survival; the same finding in a multivariate analysis suggests that the prognostic value is additional to what could be obtained from demographic and clinical characteristics. For the current analysis, all were assessed as binary categorical variables: KPS (&#x0003c;90 vs &#x02265;90), estrogen receptor status (positive vs negative), progesterone receptor status (positive vs negative), presence of visceral disease (yes vs no), age (&#x0003c;65 vs &#x02265;65), prior radiotherapy (yes vs no), prior hormonal treatment (yes vs no), menopausal status (pre- or peri-menopausal vs post-menopausal), basis for pathologic diagnosis (histological vs cytological), race (Caucasian vs non-Caucasian), and pathologic diagnosis (ductal vs non-ductal). Kaplan-Meier curves and log-rank tests were used to compare survival among patient groups categorized into three and two categories for the BPI-SF [<xref ref-type="bibr" rid="CR56">56</xref>] and the RSCL respectively. The categories of the BPI-SF were divided into approximately equal numbers of patients: worst pain scores (0&#x02009;=&#x02009;no pain, 1 to 4&#x02009;=&#x02009;mild pain, 5 to 10&#x02009;=&#x02009;moderate/severe pain), pain interference scores (0 to &#x0003c;0.5&#x02009;=&#x02009;no interference, &#x02265;0.5 to &#x0003c;4.5&#x02009;=&#x02009;mild interference, &#x02265;4.5 to &#x02264;10&#x02009;=&#x02009;moderate/severe interference). Dichotomized patient groups (&#x0003e;median, &#x02264; median) were evaluated for each of the four RSCL subscale scores; a choice of baseline median as the cut point was made by the study team so as to evaluate similar numbers of patients above and below the median. Statistical significance was defined as <italic>p</italic>&#x02009;&#x02264;&#x02009;0.05, and no adjustment was made for multiplicity. All statistical analyses were conducted using SAS&#x000ae; version 9.2 or later version.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Patient population and baseline characteristics</title><p>Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> shows the baseline demographic and disease characteristics of patients who contributed data to this analysis. This analysis included all patients who completed the BPI-SF (<italic>n</italic>&#x02009;=&#x02009;286) and RSCL (<italic>n</italic>&#x02009;=&#x02009;336) questionnaires at baseline. Approximately one-third to one-half of patients in the original study did not complete these assessments primarily due to a lack of a validated translation of the questionnaire in their language [<xref ref-type="bibr" rid="CR46">46</xref>]. Patient demographic and clinical characteristics were comparable between those who completed the BPI-SF or the RSCL, with the majority of patients less than 65&#x000a0;years of age, post-menopausal, Caucasian, and having metastatic disease at diagnosis. Additionally, similar proportions of patients in each group were estrogen or progesterone receptor positive or negative, had ductal or non-ductal breast carcinoma, and received prior radiotherapy or hormonal therapy. The number of patients eligible to complete the RSCL based on validated translations was 368. However, 32 patients did not complete the RSCL at baseline due to failure by the site to administer (<italic>n</italic>&#x02009;=&#x02009;11), patient refusal (<italic>n</italic>&#x02009;=&#x02009;11), or other reasons, the specifics of which were not documented (<italic>n</italic>&#x02009;=&#x02009;10). The number of patients eligible to complete the BPI based on validated translations was 308. Of these, 22 patients did not complete the BPI at baseline due to failure by the site to administer (<italic>n</italic>&#x02009;=&#x02009;8), patient refusal (<italic>n</italic>&#x02009;=&#x02009;9), or other reasons (<italic>n</italic>&#x02009;=&#x02009;5).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline Demographic and Disease Characteristics for Patients Who Provided BPI-SF or RSCL at Baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>BPI-SF patients</th><th>RSCL patients</th></tr></thead><tbody><tr><td>Number of patients with baseline assessment</td><td>286</td><td>336</td></tr><tr><td>Age, median (range)</td><td>55 (27&#x02013;83)</td><td>54 (27&#x02013;83)</td></tr><tr><td>Age&#x02009;&#x02265;&#x02009;65&#x000a0;years (<italic>n</italic>, %)</td><td>56 (19.6)</td><td>59 (17.6)</td></tr><tr><td colspan="3">Ethnicity, <italic>n</italic> (%)</td></tr><tr><td>&#x02003;Caucasian</td><td>202 (70.6)</td><td>220 (65.5)</td></tr><tr><td>&#x02003;Asian</td><td>15 (5.2)</td><td>16 (4.8)</td></tr><tr><td>&#x02003;Hispanic</td><td>55 (19.2)</td><td>86 (25.6)</td></tr><tr><td>&#x02003;Other</td><td>14 (4.9)</td><td>14 (4.2)</td></tr><tr><td colspan="3">Stage at entry (<italic>n</italic>, %)</td></tr><tr><td>&#x02003;Unresectable</td><td>14 (4.9)</td><td>15 (4.5)</td></tr><tr><td>&#x02003;Metastatic</td><td>272 (95.1)</td><td>321 (95.5)</td></tr><tr><td colspan="3">Karnofsky Performance Status (<italic>n</italic>, %)</td></tr><tr><td>&#x02003;&#x02009;&#x0003c;&#x02009;90</td><td>75 (26.2)</td><td>86 (25.6)</td></tr><tr><td>&#x02003;90 or 100</td><td>210 (73.4)</td><td>249 (74.1)</td></tr><tr><td>&#x02003;Unknown</td><td>1 (0.3)</td><td>1 (0.3)</td></tr><tr><td colspan="3">Tumor metastatic site (<italic>n</italic>, %)</td></tr><tr><td>&#x02003;Visceral</td><td>213 (74.5)</td><td>251 (74.7)</td></tr><tr><td>&#x02003;Non-visceral only</td><td>73 (25.5)</td><td>85 (25.3)</td></tr><tr><td colspan="3">Menopausal status</td></tr><tr><td>&#x02003;Peri-menopausal</td><td>10 (3.6)</td><td>12 (3.6)</td></tr><tr><td>&#x02003;Post-menopausal</td><td>237 (84.3)</td><td>277 (83.7)</td></tr><tr><td>&#x02003;Pre-menopausal</td><td>34 (12.1)</td><td>42 (12.7)</td></tr><tr><td>&#x02003;Unknown</td><td>5 (1.7)</td><td>5 (1.5)</td></tr><tr><td colspan="3">Estrogen receptor status (<italic>n</italic>, %)</td></tr><tr><td>&#x02003;Positive</td><td>117 (40.9)</td><td>133 (39.6)</td></tr><tr><td>&#x02003;Negative</td><td>120 (42.0)</td><td>141 (42.0)</td></tr><tr><td>&#x02003;Unknown</td><td>49 (17.1)</td><td>62 (18.5)</td></tr><tr><td colspan="3">Progesterone receptor status</td></tr><tr><td>&#x02003;Positive</td><td>101 (35.3)</td><td>113 (33.6)</td></tr><tr><td>&#x02003;Negative</td><td>123 (43.0)</td><td>146 (43.5)</td></tr><tr><td>&#x02003;Unknown</td><td>62 (21.7)</td><td>77 (22.9)</td></tr><tr><td colspan="3">Pathologic diagnosis</td></tr><tr><td>&#x02003;Ductal breast carcinoma</td><td>228 (79.7)</td><td>276 (82.1)</td></tr><tr><td>&#x02003;Non-ductal breast carcinoma</td><td>58 (20.3)</td><td>60 (17.9)</td></tr><tr><td colspan="3">Basis for pathologic diagnosis</td></tr><tr><td>&#x02003;Histopathological</td><td>257 (89.9)</td><td>303 (90.2)</td></tr><tr><td>&#x02003;Cytological</td><td>29 (10.1)</td><td>33 (9.8)</td></tr><tr><td colspan="3">Prior radiotherapy</td></tr><tr><td>&#x02003;Yes</td><td>196 (68.5)</td><td>238 (70.8)</td></tr><tr><td>&#x02003;No</td><td>90 (31.5)</td><td>98 (29.2)</td></tr><tr><td colspan="3">Prior hormone therapy</td></tr><tr><td>&#x02003;Yes</td><td>151 (52.8)</td><td>164 (48.8)</td></tr><tr><td>&#x02003;No</td><td>135 (47.2)</td><td>172 (51.2)</td></tr></tbody></table><table-wrap-foot><p>
<italic>BPI-SF</italic> Brief Pain Inventory-Short Form, <italic>RSCL</italic> Rotterdam Symptom Checklist</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec8"><title>Association of the BPI-SF and RSCL Scores with KPS</title><p>Given the role of clinician-assessed performance status as a clinical measure in these patients, we sought to specifically characterize the association between patient-assessed BPI-SF and RSCL versus KPS. Both BPI-SF variables (pain interference and worst pain) were significantly associated with KPS (pain interference <italic>p</italic>&#x02009;&#x02264;&#x02009;0.0001; worst pain <italic>p</italic>&#x02009;=&#x02009;0.0030). Patients with better performance status (higher KPS) had less pain interference and less intensity of worst pain (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). There was a positive association between mean RSCL subscale scores and KPS for activity level, physical distress, and overall HRQOL, indicating that patients with better performance status had greater levels of activity and HRQOL as well as lower levels of physical distress (all <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). While there was a positive trend in RSCL scores with increasing KPS, there was no significant association between KPS and the psychological distress subscale (<italic>p</italic>&#x02009;=&#x02009;0.1630).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Mean BPI-SF<sup>a</sup> by KPS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>KPS</th><th colspan="2">BPI-SF &#x02013; Pain Interference</th><th colspan="2">BPI-SF &#x02013; Worst Pain</th></tr><tr><th/><th>
<italic>n</italic>
</th><th>Mean (SD)</th><th>
<italic>n</italic>
</th><th>Mean (SD)</th></tr></thead><tbody><tr><td>Overall<sup>b</sup>
</td><td>281</td><td align="center">2.2 (2.63)</td><td char="." align="char">278</td><td align="center">3.2 (3.03)</td></tr><tr><td>&#x02264;70</td><td>23</td><td align="center">4.6 (3.67)</td><td char="." align="char">23</td><td align="center">4.6 (3.60)</td></tr><tr><td>80</td><td>51</td><td align="center">2.8 (2.75)</td><td char="." align="char">49</td><td align="center">4.1 (2.82)</td></tr><tr><td>90</td><td>100</td><td align="center">1.9 (2.38)</td><td char="." align="char">100</td><td align="center">3.3 (2.88)</td></tr><tr><td>100</td><td>107</td><td align="center">1.6 (2.19)</td><td char="." align="char">106</td><td align="center">2.5 (2.94)</td></tr><tr><td/><td/><td align="center">
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001<sup>c</sup>
</td><td/><td align="center">
<italic>p</italic>&#x02009;=&#x02009;0.0030<sup>c</sup>
</td></tr></tbody></table><table-wrap-foot><p>
<italic>BPI-SF</italic> Brief Pain Inventory-Short Form, <italic>KPS</italic> Karnofsky Performance Status, <italic>SD</italic> standard deviation</p><p>
<sup>a</sup>BPI-SF item scores range from 0 (no pain or interference with daily living) to 10</p><p>
<sup>b</sup>Overall patient numbers&#x02009;&#x0003c;&#x02009;286 because not all answered every BPI-SF item <sup>c</sup>
<italic>P</italic>-values derived from one-way analysis of variance</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Mean RSCL<sup>a</sup> Subscale Scores by KPS</p></caption><table frame="hsides" rules="groups"><thead><tr><th>KPS</th><th colspan="2">RSCL &#x02013; Activity</th><th colspan="2">RSCL &#x02013; Physical</th><th colspan="2">RSCL &#x02013; Psych</th><th colspan="2">RSCL &#x02013; HRQOL</th></tr><tr><th/><th>
<italic>n</italic>
</th><th>Mean (SD)</th><th>
<italic>n</italic>
</th><th>Mean (SD)</th><th>
<italic>n</italic>
</th><th>Mean (SD)</th><th>
<italic>n</italic>
</th><th>Mean (SD)</th></tr></thead><tbody><tr><td>Overall<sup>b</sup>
</td><td>329</td><td char="." align="char">83.3 (22.65)</td><td char="." align="char">333</td><td char="." align="char">83.5 (12.37)</td><td char="." align="char">332</td><td char="." align="char">64.4 (23.76)</td><td char="." align="char">323</td><td char="." align="char">66.0 (24.14)</td></tr><tr><td>&#x02264;70</td><td>25</td><td char="." align="char">51.2 (27.11)</td><td char="." align="char">26</td><td char="." align="char">74.4 (14.21)</td><td char="." align="char">26</td><td char="." align="char">56.5 (26.78)</td><td char="." align="char">26</td><td char="." align="char">38.5 (28.19)</td></tr><tr><td>80</td><td>58</td><td char="." align="char">71.7 (26.25)</td><td char="." align="char">59</td><td char="." align="char">78.5 (12.27)</td><td char="." align="char">58</td><td char="." align="char">60.3 (23.31)</td><td char="." align="char">58</td><td char="." align="char">58.6 (22.13)</td></tr><tr><td>90</td><td>110</td><td char="." align="char">85.2 (18.62)</td><td char="." align="char">111</td><td char="." align="char">84.9 (11.75)</td><td char="." align="char">111</td><td char="." align="char">65.1 (24.19)</td><td char="." align="char">109</td><td char="." align="char">67.1 (22.39)</td></tr><tr><td>100</td><td>136</td><td char="." align="char">92.7 (14.32)</td><td char="." align="char">137</td><td char="." align="char">86.2 (11.17)</td><td char="." align="char">137</td><td char="." align="char">67.1 (22.67)</td><td char="." align="char">130</td><td char="." align="char">74.0 (20.54)</td></tr><tr><td/><td/><td>
<italic>p</italic>&#x02009;=&#x02009;0.0001<sup>c</sup>
</td><td/><td>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001<sup>c</sup>
</td><td/><td>
<italic>p</italic>&#x02009;=&#x02009;0.1630<sup>c</sup>
</td><td/><td>
<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001<sup>c</sup>
</td></tr></tbody></table><table-wrap-foot><p>Activity: Activity level; Physical: Physical distress; Psych: Psychological distress</p><p>
<italic>HRQOL</italic> health-related quality of life; <italic>KPS</italic> Karnofsky Performance Status; <italic>RSCL</italic> Rotterdam Symptom Checklist; <italic>SD</italic> standard deviation</p><p>
<sup>a</sup> RSCL scores transformed to a range from 0 to 100, with 100 as best score</p><p>
<sup>b</sup> Overall patient numbers&#x02009;&#x0003c;&#x02009;336 because not all answered every RSCL item</p><p>
<sup>c</sup>
<italic>p</italic>-values derived from one-way analysis of variance</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Prognostic Effect of BPI-SF and RSCL on Survival</title><p>In the univariate analyses, patients with higher BPI-SF scores (indicating worse pain or pain interference) had lower survival rates. In the case of the RSCL, patients with higher scores (indicating lower symptom burden) had better survival. Significant prognostic effects on survival were observed for baseline scores of both BPI-SF worst pain and pain interference (both hazard ratios [HRs], 1.07 for 1-point increase; both <italic>p</italic>&#x02009;&#x02264;&#x02009;0.0061) and three of the four RSCL subscales (activity level, physical distress, and overall HRQOL) (HR, 0.86&#x02013;0.91 for 10-point increase; all <italic>p</italic>&#x02009;&#x02264;&#x02009;0.0104; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Psychological distress had no significant prognostic effect on survival.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Prognostic Effect of BPI-SF and RSCL on Survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">HRQOL subscale variables <sup>a</sup>
</th><th>
<italic>n</italic>
<sup>b</sup>
</th><th>HR</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic>-value</th><th>HR</th><th>95&#x000a0;% CI</th><th>
<italic>p</italic>-value</th></tr><tr><th/><th colspan="3">Univariate</th><th colspan="3">Multivariate<sup>c</sup>
</th></tr></thead><tbody><tr><td>BPI-SF &#x02013; Pain Interference</td><td>282</td><td char="." align="char">1.07</td><td>1.02&#x02013;1.12</td><td>0.0061</td><td char="." align="char">1.02</td><td>0.97&#x02013;1.08</td><td char="." align="char">0.3931</td></tr><tr><td>BPI-SF &#x02013; Worst Pain</td><td>279</td><td char="." align="char">1.07</td><td>1.03&#x02013;1.12</td><td>0.0013</td><td char="." align="char">1.05</td><td>1.00&#x02013;1.10</td><td char="." align="char">0.0342</td></tr><tr><td>RSCL &#x02013; Activity Level</td><td>330</td><td char="." align="char">0.86</td><td>0.82&#x02013;0.91</td><td>&#x0003c;0.0001</td><td char="." align="char">0.89</td><td>0.83&#x02013;0.95</td><td char="." align="char">0.0004</td></tr><tr><td>RSCL &#x02013; Physical Distress</td><td>333</td><td char="." align="char">0.88</td><td>0.81&#x02013;0.97</td><td>0.0104</td><td char="." align="char">0.92</td><td>0.83&#x02013;1.02</td><td char="." align="char">0.1053</td></tr><tr><td>RSCL &#x02013; Psychological Distress</td><td>332</td><td char="." align="char">0.96</td><td>0.91&#x02013;1.01</td><td>0.1025</td><td char="." align="char">0.98</td><td>0.92&#x02013;1.03</td><td char="." align="char">0.3800</td></tr><tr><td>RSCL &#x02013; HRQOL</td><td>324</td><td char="." align="char">0.91</td><td>0.87&#x02013;0.96</td><td>0.0002</td><td char="." align="char">0.95</td><td>0.90&#x02013;1.01</td><td char="." align="char">0.0810</td></tr></tbody></table><table-wrap-foot><p>
<italic>BPI-SF</italic> Brief Pain Inventory-Short Form; <italic>CI</italic> confidence interval; <italic>HR</italic> hazard ratio; <italic>HRQOL</italic> health-related quality of life; <italic>KPS</italic> Karnofsky Performance Status; <italic>n</italic> number of patients with nonmissing values on a variable among randomized patients; <italic>RSCL</italic> Rotterdam Symptom Checklist</p><p>
<sup>a</sup>HRs for every 1-point increase in the BPI-SF and every 10-point increase in the RSCL subscales</p><p>
<sup>b</sup>Includes 1 patient with missing KPS score and not included in Tables&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>. This patient&#x02019;s scores were as follows: BPI Pain Interference, 0; BPI Worst Pain, 0; RSCL Activity, 100; RSCL Physical, missing; RSCL Psychological, missing; RSCL HRQOL, 83.33</p><p>
<sup>c</sup>Multivariate Cox proportional hazards models were used to determine each HR in the presence of 11 demographic/clinical variables: age, race, KPS, estrogen receptor status, progesterone receptor status, presence of visceral disease, prior radiotherapy, prior hormonal treatment, menopausal status, basis for pathological diagnosis, and pathological diagnosis</p></table-wrap-foot></table-wrap></p><p>In the multivariate analyses, the BPI-SF worst pain item and the RSCL activity level remained significant prognostic factors (<italic>p</italic>&#x02009;=&#x02009;0.0342, <italic>p</italic>&#x02009;=&#x02009;0.0004, respectively; Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>) in the presence of the 11 baseline demographic or clinical variables. The pain interference subscale, physical distress, and overall HRQOL scores were no longer significant. Consistent with the univariate analysis, psychological distress was not prognostic for survival.</p></sec><sec id="Sec10"><title>Survival Time by BPI-Worst Pain, Pain Interference, and RSCL Categories</title><p>The median survival time for patients with a BPI-SF worst pain score of 0 (no pain) was 23.8&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;91), versus 17.9&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;94) for scores 1&#x02013;4, and 14.6&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;94) for scores 5&#x02013;10 (log-rank <italic>p</italic>&#x02009;=&#x02009;0.0065, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref>). Median survival time for patients with BPI-SF pain interference scores was 21.2&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;113) (no pain; scores 0 to &#x0003c;0.5) versus 17.6&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;111) (scores &#x02265;0.5 to &#x0003c;4.5) and 14.8&#x000a0;months (<italic>n</italic>&#x02009;=&#x02009;58) (scores &#x02265;4.5 to &#x02264;10; log-rank <italic>p</italic>&#x02009;=&#x02009;0.0107; Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b</xref>). The median survival time was 23.8&#x000a0;months for patients with median (95.2) or greater activity level scores versus 14.6&#x000a0;months for patients with scores below median (log-rank <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.0001, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Similarly, for the activity, physical, psychological, and HRQOL subscales, patients with median or greater scores had significantly better survival (log-rank <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Kaplan-Meier Survival Curves by BPI-Worst Pain Categories. <bold>a</bold> Worst Pain <bold>b</bold> Pain Interference</p></caption><graphic xlink:href="12955_2016_449_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Kaplan-Meier Survival Curves by Rotterdam Symptom Checklist (RSCL) Categories. <bold>a</bold>. Activity Level. <bold>b</bold>. Physical Distress. <bold>c</bold>. Psychological Distress. <bold>d</bold>. Overall Health-Related Quality of Life (HRQOL). * Multivariate Cox proportional hazards models were used to determine each hazard ratio (HR) in the presence of 11 demographic/clinical variables: age, race, KPS, estrogen receptor status, progesterone receptor status, presence of visceral disease, prior radiotherapy, prior hormonal treatment, menopausal status, basis for pathological diagnosis, and pathological diagnosis. Reference is the &#x0003c; median group; Q50 is the median of each RSCL subscale</p></caption><graphic xlink:href="12955_2016_449_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec11" sec-type="discussion"><title>Discussion</title><p>We have shown in this post hoc analysis that baseline patient-reported outcomes and symptoms, as measured by the BPI-SF and RSCL, were prognostic for survival in patients with locally recurrent or metastatic breast carcinoma who received gemcitabine with or without paclitaxel. The use of two different, validated instruments was informative when exploring this prognostic effect in that they measure distinct aspects of HRQOL in cancer patients [<xref ref-type="bibr" rid="CR57">57</xref>], and the present study allowed for a model-dependent sensitivity analysis.</p><p>In this study, the worst pain and pain interference measures of the BPI-SF as well as activity level, physical distress, and HRQOL scores of the RSCL were all prognostic for survival in the univariate analysis. The BPI-SF worst pain and RSCL activity subscales retained a statistically significant effect in the multivariate analysis, which incorporated clinical, and sociodemographic variables commonly used as prognostic indicators in advanced breast cancer (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). Clinical factors previously reported as prognostic via multivariate analysis for this study cohort included time from diagnosis to randomization, number of tumor sites, estrogen receptor status, and KPS [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>The RSCL activity subscale had the greatest effect on survival, as reflected by the hazard ratio in the univariate analysis (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). In addition, it was the only subscale to retain a statistically significant effect in the multivariate analysis that considered the other RSCL subscales as well as baseline clinical or demographic characteristics. The RSCL psychological distress subscale had no relationship with survival based on 10-point increments in a Cox proportional hazards model (Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>). However, the dichotomous comparison (above and below median scores) did reveal a significant difference in survival curves (log-rank <italic>p</italic>&#x02009;=&#x02009;0.0109; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). It is important to note that systematic literature reviews have found only minimal evidence for prognostic effects of psychosocial HRQOL domains on cancer survival [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR58">58</xref>].</p><p>The most commonly utilized instruments in MBC trials include the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the EORTC QLQ-C30 with or without the EORTC breast cancer-specific module, QLQ-BR23 [<xref ref-type="bibr" rid="CR59">59</xref>]; positive prognostic results have been demonstrated in previously reported analyses of advanced breast cancer that used baseline EORTC QLC-C30 assessments [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>The current exploratory analysis of a clinical study population further adds to the body of evidence that patient-reported outcomes and symptoms can be prognostic indicators in patients with advanced breast cancer and as such, a useful adjunct for informing the routine care of patients. It is important to note that because patient-reported responses can be subject to social and environmental factors, this information is best used as an added tool to all other demographic and clinical considerations that are part of patient care [<xref ref-type="bibr" rid="CR9">9</xref>]. The reasons for the relationship between patient-reported outcomes and symptoms, and survival have not been completely elucidated. However, it is thought that patient-reported outcomes may be sensitive to disease progression or markers of patient behaviors or other characteristics, such as treatment adherence or healthy lifestyles [<xref ref-type="bibr" rid="CR7">7</xref>]. In addition, the inclusion of multiple items in patient survey instruments may enhance their diagnostic sensitivity whether in clinical management or in oncology drug trials [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>It is important to reiterate that the current study was a post hoc analysis of HRQOL data originally recorded as secondary outcomes in a prospective clinical trial [<xref ref-type="bibr" rid="CR46">46</xref>]. Although not all randomized patients were included in the analyses due to limited availability of translations of the BPI-SF and RSCL, a high percentage of the patients with translations available to them completed the questionnaires; furthermore because only baseline questionnaire responses were used, there was less potential for nonrandom missing data. Prognostic factors in the current study were not defined prior to study enrollment, and no adjustments were made for multiplicity. Therefore, it would be worthwhile to evaluate the hypothesis prospectively in order to further support the utility of patient-survey instruments for the added benefit of assessing patient prognosis both in clinical trials as well as in routine clinical practice. If confirmed, these data could be used to potentially identify appropriate cut points for the purposes of prognostic evaluation and study stratification. It is important to reiterate that these findings are specific to first-line advanced disease and cannot be generalized to other lines of therapy. Furthermore, results discordant with those of other studies may have been due to differences in statistical techniques or instrumentation.</p></sec><sec id="Sec12"><title>Conclusion</title><p>In conclusion, this post hoc analysis of patients with advanced breast cancer showed that pretreatment BPI-SF worst pain and RSCL activity scores provide additional prognostic information for survival beyond that available from standard demographic and clinical characteristics. Our findings further support the concept that patient-reported outcomes can be useful additional prognostic factors in advanced breast cancer and help guide effective clinical decision making by revealing manifestations of malignant disease not systematically evaluated by formal clinical measures.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BPI-SF</term><def><p>Brief Pain Inventory Short Form</p></def></def-item><def-item><term>EORTC QLQ-C30</term><def><p>European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30</p></def></def-item><def-item><term>HR</term><def><p>hazard ratio.</p></def></def-item><def-item><term>HRQOL</term><def><p>health related quality of life</p></def></def-item><def-item><term>KPS</term><def><p>Karnofsky Performance Status</p></def></def-item><def-item><term>MBC</term><def><p>metastatic breast cancer</p></def></def-item><def-item><term>RSCL</term><def><p>Rotterdam Symptom Checklist</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>ENS, WS, LB, PP, WJ, AM, and AML are employees and shareholders at Eli Lilly and Company.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>WS and LB originated the concept and design of the study; WS performed data acquisition; WS, PP, LB, and ENS were responsible for statistical analyses/interpretation; ENS and WS drafted the manuscript. All authors revised the manuscript for important intellectual content and approved the final version.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The study, the development of this manuscript, and article processing charge were supported by Eli Lilly and Company. We thank Zhanglin Lin Cui and Jiaying Guo of Eli Lilly and Company for their assistance in statistical analysis. We also thank David Hartree of ClinGenuity, LLC, Cincinnati, USA, for writing assistance, which was supported by Eli Lilly and Company.</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">American Cancer Society. Global Cancer Facts &#x00026; Figures 2nd Edition. American Cancer Society, Atlanta. 2011. <ext-link ext-link-type="uri" xlink:href="http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf">http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf</ext-link>. Accessed 4 Aug, 2014.</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benson</surname><given-names>JR</given-names></name><name><surname>Jatoi</surname><given-names>I</given-names></name></person-group><article-title>The global breast cancer burden</article-title><source>Future Oncol</source><year>2012</year><volume>8</volume><fpage>697</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.2217/fon.12.61</pub-id><pub-id pub-id-type="pmid">22764767</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Swain S, Kim S, Cortes J, J. R, Semiglazov V, Campone M, et al. 350O_PR - Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1&#x000a0;L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). European Society for Medical Oncology; 28.09.2014; Madrid, Spain 2014.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>SH</given-names></name><name><surname>Wolff</surname><given-names>AC</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Harris</surname><given-names>JR</given-names></name><name><surname>Lippman</surname><given-names>ME</given-names></name><name><surname>Morrow</surname><given-names>M</given-names></name><name><surname>Osborne</surname><given-names>CK</given-names></name></person-group><article-title>Treatment of Metastatic Breast Cancer: Chemotherapy</article-title><source>Diseases of the Breast</source><year>2010</year><edition>4</edition><publisher-loc>Philadelphia, PA</publisher-loc><publisher-name>Lippincott-Raven Publishers</publisher-name><fpage>877</fpage><lpage>919</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montazeri</surname><given-names>A</given-names></name></person-group><article-title>Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007</article-title><source>J Exp Clin Cancer Res</source><year>2008</year><volume>27</volume><fpage>32</fpage><pub-id pub-id-type="doi">10.1186/1756-9966-27-32</pub-id><pub-id pub-id-type="pmid">18759983</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganz</surname><given-names>PA</given-names></name></person-group><article-title>Survivorship: adult cancer survivors</article-title><source>Prim Care</source><year>2009</year><volume>36</volume><fpage>721</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/j.pop.2009.08.001</pub-id><pub-id pub-id-type="pmid">19913184</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotay</surname><given-names>CC</given-names></name><name><surname>Kawamoto</surname><given-names>CT</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Efficace</surname><given-names>F</given-names></name></person-group><article-title>The prognostic significance of patient-reported outcomes in cancer clinical trials</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>1355</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.13.3439</pub-id><pub-id pub-id-type="pmid">18227528</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>PW</given-names></name><name><surname>Nelson</surname><given-names>JB</given-names></name><name><surname>Mulani</surname><given-names>PM</given-names></name><name><surname>Sleep</surname><given-names>D</given-names></name></person-group><article-title>Quality of life as a potential predictor for morbidity and mortality in patients with metastatic hormone-refractory prostate cancer</article-title><source>Qual Life Res</source><year>2006</year><volume>15</volume><fpage>1297</fpage><lpage>1306</lpage><pub-id pub-id-type="doi">10.1007/s11136-006-0003-2</pub-id><pub-id pub-id-type="pmid">16830258</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohr</surname><given-names>KN</given-names></name><name><surname>Zebrack</surname><given-names>BJ</given-names></name></person-group><article-title>Using patient-reported outcomes in clinical practice: challenges and opportunities</article-title><source>Qual Life Res</source><year>2009</year><volume>18</volume><fpage>99</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1007/s11136-008-9413-7</pub-id><pub-id pub-id-type="pmid">19034690</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detmar</surname><given-names>SB</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name></person-group><article-title>Quality of life assessment in daily clinical oncology practice: a feasibility study</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><issue>8</issue><fpage>1181</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(98)00018-5</pub-id><pub-id pub-id-type="pmid">9849476</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>AB</given-names></name><name><surname>Selby</surname><given-names>PJ</given-names></name></person-group><article-title>Computer-based quality of life questionnaires may contribute to doctor-patient interactions in oncology</article-title><source>Br J Cancer</source><year>2002</year><volume>86</volume><fpage>51</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6600001</pub-id><pub-id pub-id-type="pmid">11857011</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velikova</surname><given-names>G</given-names></name><name><surname>Booth</surname><given-names>L</given-names></name><name><surname>Smith</surname><given-names>AB</given-names></name><name><surname>Brown</surname><given-names>PM</given-names></name><name><surname>Lynch</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>714</fpage><lpage>724</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.06.078</pub-id><pub-id pub-id-type="pmid">14966096</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detmar</surname><given-names>SB</given-names></name><name><surname>Muller</surname><given-names>MJ</given-names></name><name><surname>Schornagel</surname><given-names>JH</given-names></name><name><surname>Wever</surname><given-names>LD</given-names></name><name><surname>Aaronson</surname><given-names>NK</given-names></name></person-group><article-title>Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>3027</fpage><lpage>3034</lpage><pub-id pub-id-type="doi">10.1001/jama.288.23.3027</pub-id><pub-id pub-id-type="pmid">12479768</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotronoulas</surname><given-names>G</given-names></name><name><surname>Kearney</surname><given-names>N</given-names></name><name><surname>Maguire</surname><given-names>R</given-names></name><name><surname>Harrow</surname><given-names>A</given-names></name><name><surname>Di Domenico</surname><given-names>D</given-names></name><name><surname>Croy</surname><given-names>S</given-names></name><etal/></person-group><article-title>What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials</article-title><source>J Clin Oncol</source><year>2014</year><volume>32</volume><fpage>1480</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.53.5948</pub-id><pub-id pub-id-type="pmid">24711559</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basch</surname><given-names>E</given-names></name><name><surname>Deal</surname><given-names>AM</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name><name><surname>Hudis</surname><given-names>CA</given-names></name><name><surname>Sabbatini</surname><given-names>P</given-names></name><etal/></person-group><article-title>Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial</article-title><source>J Clin Oncol</source><year>2016</year><volume>34</volume><fpage>557</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.63.0830</pub-id><pub-id pub-id-type="pmid">26644527</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howell</surname><given-names>D</given-names></name><name><surname>Molloy</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>K</given-names></name><name><surname>Green</surname><given-names>E</given-names></name><name><surname>Orchard</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><etal/></person-group><article-title>Patient-reported outcomes in routine cancer clinical practice: a scoping review of use, impact on health outcomes, and implementation factors</article-title><source>Ann Oncol</source><year>2015</year><volume>26</volume><issue>9</issue><fpage>1846</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdv181</pub-id><pub-id pub-id-type="pmid">25888610</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cardoso</surname><given-names>F</given-names></name><name><surname>Senkus-Konefka</surname><given-names>E</given-names></name><name><surname>Fallowfield</surname><given-names>L</given-names></name><name><surname>Costa</surname><given-names>A</given-names></name><name><surname>Castiglione</surname><given-names>M</given-names></name></person-group><article-title>Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up</article-title><source>Ann Oncol</source><year>2010</year><volume>21</volume><issue>Suppl 5</issue><fpage>v15</fpage><lpage>v19</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq160</pub-id><pub-id pub-id-type="pmid">20555067</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moinpour</surname><given-names>CM</given-names></name><name><surname>Feigl</surname><given-names>P</given-names></name><name><surname>Metch</surname><given-names>B</given-names></name><name><surname>Hayden</surname><given-names>KA</given-names></name><name><surname>Meyskens</surname><given-names>FL</given-names><suffix>Jr</suffix></name><name><surname>Crowley</surname><given-names>J</given-names></name></person-group><article-title>Quality of life end points in cancer clinical trials: review and recommendations</article-title><source>J Natl Cancer Inst</source><year>1989</year><volume>81</volume><fpage>485</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1093/jnci/81.7.485</pub-id><pub-id pub-id-type="pmid">2646455</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nieder</surname><given-names>C</given-names></name><name><surname>Mehta</surname><given-names>MP</given-names></name></person-group><article-title>Prognostic indices for brain metastases--usefulness and challenges</article-title><source>Radiat Oncol</source><year>2009</year><volume>4</volume><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/1748-717X-4-10</pub-id><pub-id pub-id-type="pmid">19261187</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>LI</given-names></name><name><surname>Wenzel</surname><given-names>L</given-names></name><name><surname>Shaw</surname><given-names>E</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name></person-group><article-title>Patient-reported outcomes in phase II cancer clinical trials: lessons learned and future directions</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>5058</fpage><lpage>5062</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.7275</pub-id><pub-id pub-id-type="pmid">17991921</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>EA</given-names></name><name><surname>Cella</surname><given-names>D</given-names></name><name><surname>Chassany</surname><given-names>O</given-names></name><name><surname>Fairclough</surname><given-names>DL</given-names></name><name><surname>Wong</surname><given-names>GY</given-names></name><name><surname>Hays</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Precision of health-related quality-of-life data compared with other clinical measures</article-title><source>Mayo Clin Proc</source><year>2007</year><volume>82</volume><fpage>1244</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.4065/82.10.1244</pub-id><pub-id pub-id-type="pmid">17908530</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sprangers</surname><given-names>MA</given-names></name></person-group><article-title>Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement</article-title><source>Acta Oncol</source><year>2010</year><volume>49</volume><fpage>155</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.3109/02841860903440288</pub-id><pub-id pub-id-type="pmid">20059312</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinten</surname><given-names>C</given-names></name><name><surname>Martinelli</surname><given-names>F</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Sprangers</surname><given-names>MA</given-names></name><name><surname>Ringash</surname><given-names>J</given-names></name><name><surname>Gotay</surname><given-names>C</given-names></name><etal/></person-group><article-title>A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites</article-title><source>Cancer</source><year>2014</year><volume>120</volume><fpage>302</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1002/cncr.28382</pub-id><pub-id pub-id-type="pmid">24127333</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>Lorigan</surname><given-names>P</given-names></name><name><surname>Szutowicz-Zielinska</surname><given-names>E</given-names></name><name><surname>Liepa</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin</article-title><source>Lung Cancer</source><year>2012</year><volume>78</volume><fpage>276</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2012.09.002</pub-id><pub-id pub-id-type="pmid">23043970</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinten</surname><given-names>C</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Mauer</surname><given-names>M</given-names></name><name><surname>Comte</surname><given-names>S</given-names></name><name><surname>Sprangers</surname><given-names>MA</given-names></name><name><surname>Cleeland</surname><given-names>C</given-names></name><etal/></person-group><article-title>Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials</article-title><source>Lancet Oncol</source><year>2009</year><volume>10</volume><fpage>865</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(09)70200-1</pub-id><pub-id pub-id-type="pmid">19695956</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coates</surname><given-names>A</given-names></name><name><surname>Gebski</surname><given-names>V</given-names></name><name><surname>Signorini</surname><given-names>D</given-names></name><name><surname>Murray</surname><given-names>P</given-names></name><name><surname>McNeil</surname><given-names>D</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><etal/></person-group><article-title>Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand Breast Cancer Trials Group</article-title><source>J Clin Oncol</source><year>1992</year><volume>10</volume><fpage>1833</fpage><lpage>1838</lpage><pub-id pub-id-type="pmid">1453197</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efficace</surname><given-names>F</given-names></name><name><surname>Biganzoli</surname><given-names>L</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>Coens</surname><given-names>C</given-names></name><name><surname>Van Steen</surname><given-names>K</given-names></name><name><surname>Cufer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer</article-title><source>Eur J Cancer</source><year>2004</year><volume>40</volume><fpage>1021</fpage><lpage>1030</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2004.01.014</pub-id><pub-id pub-id-type="pmid">15093577</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>JA</given-names></name><name><surname>Curran</surname><given-names>D</given-names></name><name><surname>Piccart</surname><given-names>M</given-names></name><name><surname>de Haes</surname><given-names>JC</given-names></name><name><surname>Bruning</surname><given-names>P</given-names></name><name><surname>Klijn</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>1498</fpage><lpage>1506</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(00)00144-1</pub-id><pub-id pub-id-type="pmid">10930797</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svensson</surname><given-names>H</given-names></name><name><surname>Hatschek</surname><given-names>T</given-names></name><name><surname>Johansson</surname><given-names>H</given-names></name><name><surname>Einbeigi</surname><given-names>Z</given-names></name><name><surname>Brandberg</surname><given-names>Y</given-names></name></person-group><article-title>Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><fpage>432</fpage><lpage>438</lpage><pub-id pub-id-type="doi">10.1007/s12032-011-9844-9</pub-id><pub-id pub-id-type="pmid">21298494</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Granick</surname><given-names>J</given-names></name><name><surname>Grutsch</surname><given-names>JF</given-names></name><name><surname>Lis</surname><given-names>CG</given-names></name></person-group><article-title>The prognostic association of health-related quality of life scores with survival in breast cancer</article-title><source>Support Care Cancer</source><year>2007</year><volume>15</volume><fpage>387</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1007/s00520-006-0165-z</pub-id><pub-id pub-id-type="pmid">17093913</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staren</surname><given-names>ED</given-names></name><name><surname>Gupta</surname><given-names>D</given-names></name><name><surname>Braun</surname><given-names>DP</given-names></name></person-group><article-title>The prognostic role of quality of life assessment in breast cancer</article-title><source>Breast J</source><year>2011</year><volume>17</volume><fpage>571</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4741.2011.01151.x</pub-id><pub-id pub-id-type="pmid">21895846</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collette</surname><given-names>L</given-names></name><name><surname>van Andel</surname><given-names>G</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Oosterhof</surname><given-names>GO</given-names></name><name><surname>Albrecht</surname><given-names>W</given-names></name><name><surname>de Reijke</surname><given-names>TM</given-names></name><etal/></person-group><article-title>Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3877</fpage><lpage>3885</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.07.089</pub-id><pub-id pub-id-type="pmid">15459209</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>VT</given-names></name><name><surname>Thaler</surname><given-names>HT</given-names></name><name><surname>Polyak</surname><given-names>TA</given-names></name><name><surname>Kornblith</surname><given-names>AB</given-names></name><name><surname>Lepore</surname><given-names>JM</given-names></name><name><surname>Portenoy</surname><given-names>RK</given-names></name></person-group><article-title>Quality of life and survival: the role of multidimensional symptom assessment</article-title><source>Cancer</source><year>1998</year><volume>83</volume><fpage>173</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0142(19980701)83:1&#x0003c;173::AID-CNCR23&#x0003e;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">9655308</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chau</surname><given-names>I</given-names></name><name><surname>Norman</surname><given-names>AR</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Waters</surname><given-names>JS</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>PJ</given-names></name></person-group><article-title>Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>2395</fpage><lpage>2403</lpage><pub-id pub-id-type="doi">10.1200/JCO.2004.08.154</pub-id><pub-id pub-id-type="pmid">15197201</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Efficace</surname><given-names>F</given-names></name><name><surname>Bottomley</surname><given-names>A</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>Lianes</surname><given-names>P</given-names></name><name><surname>Legrand</surname><given-names>C</given-names></name><name><surname>Debruyne</surname><given-names>C</given-names></name><etal/></person-group><article-title>Is a patient&#x02019;s self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975</article-title><source>Ann Oncol</source><year>2006</year><volume>17</volume><fpage>1698</fpage><lpage>1704</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdl183</pub-id><pub-id pub-id-type="pmid">16968876</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKernan</surname><given-names>M</given-names></name><name><surname>McMillan</surname><given-names>DC</given-names></name><name><surname>Anderson</surname><given-names>JR</given-names></name><name><surname>Angerson</surname><given-names>WJ</given-names></name><name><surname>Stuart</surname><given-names>RC</given-names></name></person-group><article-title>The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer</article-title><source>Br J Cancer</source><year>2008</year><volume>98</volume><fpage>888</fpage><lpage>893</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6604248</pub-id><pub-id pub-id-type="pmid">18268490</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Movsas</surname><given-names>B</given-names></name><name><surname>Moughan</surname><given-names>J</given-names></name><name><surname>Sarna</surname><given-names>L</given-names></name><name><surname>Langer</surname><given-names>C</given-names></name><name><surname>Werner-Wasik</surname><given-names>M</given-names></name><name><surname>Nicolaou</surname><given-names>N</given-names></name><etal/></person-group><article-title>Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801</article-title><source>J Clin Oncol</source><year>2009</year><volume>27</volume><fpage>5816</fpage><lpage>5822</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.7420</pub-id><pub-id pub-id-type="pmid">19858383</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloan</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Novotny</surname><given-names>PJ</given-names></name><name><surname>Wampfler</surname><given-names>J</given-names></name><name><surname>Garces</surname><given-names>Y</given-names></name><name><surname>Clark</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Relationship between deficits in overall quality of life and non-small-cell lung cancer survival</article-title><source>J Clin Oncol</source><year>2012</year><volume>30</volume><fpage>1498</fpage><lpage>1504</lpage><pub-id pub-id-type="doi">10.1200/JCO.2010.33.4631</pub-id><pub-id pub-id-type="pmid">22454418</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>AD</given-names></name><name><surname>Novotny</surname><given-names>PJ</given-names></name><name><surname>Kaur</surname><given-names>JS</given-names></name><name><surname>Buckner</surname><given-names>JC</given-names></name><name><surname>Schaefer</surname><given-names>PL</given-names></name><name><surname>Stella</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>A patient-level meta-analytic investigation of the prognostic significance of baseline quality of life (QOL) for overall survival (OS) among 3,704 patients participating in 24 North Central Cancer Treatment Group (NCCTG) and Mayo Clinic Cancer Center (MC) oncology clinical trials</article-title><source>J Clin Oncol</source><year>2007</year><volume>26</volume><issue>Suppl1</issue><fpage>9515</fpage></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albain</surname><given-names>KS</given-names></name><name><surname>Nag</surname><given-names>SM</given-names></name><name><surname>Calderillo-Ruiz</surname><given-names>G</given-names></name><name><surname>Jordaan</surname><given-names>JP</given-names></name><name><surname>Llombart</surname><given-names>AC</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><etal/></person-group><article-title>Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>3950</fpage><lpage>3957</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.9362</pub-id><pub-id pub-id-type="pmid">18711184</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Cleeland C. The Brief Pain Inventory: A Users Guide. 2009. <ext-link ext-link-type="uri" xlink:href="http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf">http://www.mdanderson.org/education-and-research/departments-programs-and-labs/departments-and-divisions/symptom-research/symptom-assessment-tools/BPI_UserGuide.pdf</ext-link>. Accessed. 2 Sept, 2014.</mixed-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Twelves</surname><given-names>CJ</given-names></name><name><surname>Dobbs</surname><given-names>NA</given-names></name><name><surname>Lawrence</surname><given-names>MA</given-names></name><name><surname>Ramirez</surname><given-names>AJ</given-names></name><name><surname>Summerhayes</surname><given-names>M</given-names></name><name><surname>Richards</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Iododoxorubicin in advanced breast cancer: a phase II evaluation of clinical activity, pharmacology and quality of life</article-title><source>Br J Cancer</source><year>1994</year><volume>69</volume><fpage>726</fpage><lpage>731</lpage><pub-id pub-id-type="doi">10.1038/bjc.1994.137</pub-id><pub-id pub-id-type="pmid">8142261</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Mastro</surname><given-names>L</given-names></name><name><surname>Fabi</surname><given-names>A</given-names></name><name><surname>Mansutti</surname><given-names>M</given-names></name><name><surname>De Laurentiis</surname><given-names>M</given-names></name><name><surname>Durando</surname><given-names>A</given-names></name><name><surname>Merlo</surname><given-names>DF</given-names></name><etal/></person-group><article-title>Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>164</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-13-164</pub-id><pub-id pub-id-type="pmid">23537313</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>AJ</given-names></name><name><surname>Towlson</surname><given-names>KE</given-names></name><name><surname>Leaning</surname><given-names>MS</given-names></name><name><surname>Richards</surname><given-names>MA</given-names></name><name><surname>Rubens</surname><given-names>RD</given-names></name></person-group><article-title>Do patients with advanced breast cancer benefit from chemotherapy?</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>1488</fpage><lpage>1494</lpage><pub-id pub-id-type="doi">10.1038/bjc.1998.711</pub-id><pub-id pub-id-type="pmid">9836482</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopwood</surname><given-names>P</given-names></name><name><surname>Watkins</surname><given-names>J</given-names></name><name><surname>Ellis</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>I</given-names></name></person-group><article-title>Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer</article-title><source>Breast J</source><year>2008</year><volume>14</volume><fpage>228</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1111/j.1524-4741.2008.00567.x</pub-id><pub-id pub-id-type="pmid">18433403</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moinpour</surname><given-names>CM</given-names></name><name><surname>Donaldson</surname><given-names>GW</given-names></name><name><surname>Liepa</surname><given-names>AM</given-names></name><name><surname>Melemed</surname><given-names>AS</given-names></name><name><surname>O&#x02019;Shaughnessy</surname><given-names>J</given-names></name><name><surname>Albain</surname><given-names>KS</given-names></name></person-group><article-title>Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer</article-title><source>Qual Life Res</source><year>2012</year><volume>21</volume><fpage>765</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1007/s11136-011-9999-z</pub-id><pub-id pub-id-type="pmid">21922153</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Ryan</surname><given-names>KM</given-names></name></person-group><article-title>Pain assessment: global use of the Brief Pain Inventory</article-title><source>Ann Acad Med Singapore</source><year>1994</year><volume>23</volume><fpage>129</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">8080219</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>de Haes</surname><given-names>JC</given-names></name><name><surname>Olschewski</surname><given-names>M</given-names></name><name><surname>Fayres</surname><given-names>P</given-names></name><name><surname>Visser</surname><given-names>MRM</given-names></name><name><surname>Cull</surname><given-names>A</given-names></name><name><surname>Hopwood</surname><given-names>P</given-names></name><etal/></person-group><source>Measuring the Quality of Life of Cancer Patients With the Rotterdam Symptom Checklist (RSCL): A Manual</source><year>2012</year><publisher-loc>Groningen, The Netherlands</publisher-loc><publisher-name>Northern Centre for Healthcare Research (NCH)</publisher-name></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Law</surname><given-names>M</given-names></name><name><surname>Maguire</surname><given-names>GP</given-names></name><name><surname>Robertson</surname><given-names>B</given-names></name><name><surname>Greer</surname><given-names>S</given-names></name><name><surname>Bliss</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Further development of a quality of life measure for cancer patients: The Rotterdam Symptom Checklist (revised)</article-title><source>Psycho-Oncology</source><year>1992</year><volume>1</volume><fpage>35</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1002/pon.2960010106</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Haes</surname><given-names>JC</given-names></name><name><surname>Olschewski</surname><given-names>M</given-names></name></person-group><article-title>Quality of life assessment in a cross-cultural context: use of the Rotterdam Symptom Checklist in a multinational randomised trial comparing CMF and Zoladex (Goserlin) treatment in early breast cancer</article-title><source>Ann Oncol</source><year>1998</year><volume>9</volume><fpage>745</fpage><lpage>750</lpage><pub-id pub-id-type="doi">10.1023/A:1008282806910</pub-id><pub-id pub-id-type="pmid">9739441</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>AJ</given-names></name><name><surname>Parmar</surname><given-names>MK</given-names></name><name><surname>Stephens</surname><given-names>RJ</given-names></name></person-group><article-title>Patient-reported short-term and long-term physical and psychologic symptoms: results of the continuous hyperfractionated accelerated radiotherapy (CHART) randomized trial in non-small-cell lung cancer. CHART Steering Committee</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>3082</fpage><lpage>3093</lpage><pub-id pub-id-type="pmid">9738579</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiarion-Sileni</surname><given-names>V</given-names></name><name><surname>Del Bianco</surname><given-names>P</given-names></name><name><surname>De Salvo</surname><given-names>GL</given-names></name><name><surname>Lo Re</surname><given-names>G</given-names></name><name><surname>Romanini</surname><given-names>A</given-names></name><name><surname>Labianca</surname><given-names>R</given-names></name><etal/></person-group><article-title>Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients</article-title><source>Eur J Cancer</source><year>2003</year><volume>39</volume><fpage>1577</fpage><lpage>1585</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(03)00372-1</pub-id><pub-id pub-id-type="pmid">12855265</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>GG</given-names></name><name><surname>Philips</surname><given-names>N</given-names></name><name><surname>Pickles</surname><given-names>T</given-names></name></person-group><article-title>Report on the quality of life analysis from the phase III trial of pion versus photon radiotherapy in locally advanced prostate cancer</article-title><source>Eur J Cancer</source><year>2000</year><volume>36</volume><fpage>759</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(99)00341-X</pub-id><pub-id pub-id-type="pmid">10762749</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopwood</surname><given-names>P</given-names></name><name><surname>Harvey</surname><given-names>A</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Stephens</surname><given-names>RJ</given-names></name><name><surname>Girling</surname><given-names>DJ</given-names></name><name><surname>Gibson</surname><given-names>D</given-names></name><etal/></person-group><article-title>Survey of the Administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. The Medical Research Council Lung Cancer Working Party the CHART Steering Committee</article-title><source>Eur J Cancer</source><year>1998</year><volume>34</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(97)00347-X</pub-id><pub-id pub-id-type="pmid">9624237</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribi</surname><given-names>K</given-names></name><name><surname>Bernhard</surname><given-names>J</given-names></name><name><surname>Schuller</surname><given-names>JC</given-names></name><name><surname>Weder</surname><given-names>W</given-names></name><name><surname>Bodis</surname><given-names>S</given-names></name><name><surname>Jorger</surname><given-names>M</given-names></name><etal/></person-group><article-title>Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes</article-title><source>Lung Cancer</source><year>2008</year><volume>61</volume><fpage>398</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2008.01.013</pub-id><pub-id pub-id-type="pmid">18433927</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cleeland</surname><given-names>CS</given-names></name><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Mendoza</surname><given-names>TR</given-names></name><name><surname>Edwards</surname><given-names>KR</given-names></name><name><surname>Douglas</surname><given-names>J</given-names></name><name><surname>Serlin</surname><given-names>RC</given-names></name></person-group><article-title>Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling</article-title><source>Pain</source><year>1996</year><volume>67</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/0304-3959(96)03131-4</pub-id><pub-id pub-id-type="pmid">8951920</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kemmler</surname><given-names>G</given-names></name><name><surname>Holzner</surname><given-names>B</given-names></name><name><surname>Kopp</surname><given-names>M</given-names></name><name><surname>Dunser</surname><given-names>M</given-names></name><name><surname>Margreiter</surname><given-names>R</given-names></name><name><surname>Greil</surname><given-names>R</given-names></name><etal/></person-group><article-title>Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30</article-title><source>J Clin Oncol</source><year>1999</year><volume>17</volume><fpage>2932</fpage><lpage>2940</lpage><pub-id pub-id-type="pmid">10561373</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montazeri</surname><given-names>A</given-names></name></person-group><article-title>Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008</article-title><source>Health Qual Life Outcomes</source><year>2009</year><volume>7</volume><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/1477-7525-7-102</pub-id><pub-id pub-id-type="pmid">20030832</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemieux</surname><given-names>J</given-names></name><name><surname>Goodwin</surname><given-names>PJ</given-names></name><name><surname>Bordeleau</surname><given-names>LJ</given-names></name><name><surname>Lauzier</surname><given-names>S</given-names></name><name><surname>Theberge</surname><given-names>V</given-names></name></person-group><article-title>Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001&#x02013;2009)</article-title><source>J Natl Cancer Inst</source><year>2011</year><volume>103</volume><fpage>178</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1093/jnci/djq508</pub-id><pub-id pub-id-type="pmid">21217081</pub-id></element-citation></ref></ref-list></back></article>